Pentadecapeptide derived from gastric protective protein. Upregulates local growth factors and angiogenesis.
Synthetic 15-amino acid sequence isolated from a region of human gastric juice protein. Animal models show accelerated tendon-to-bone healing, vascular regeneration, and gut barrier repair via VEGFR2-Akt-eNOS signaling. Human evidence is preliminary — most clinical claims trace back to rodent studies.
Distilled themes from named communities — Reddit threads, forums, creator commentary. Not direct quotes; not clinical evidence. Useful for calibrating expectations against what real self-experimenters report.
Most-cited use is post-injury joint and tendon recovery. Typical dose lands at 250-500 µg/day subcutaneous, run for 4-6 weeks then off. Some users prefer local injection at the injury site (e.g., directly around a sore tendon); others go systemic. Subjective onset reports cluster around 7-14 days.
BPC-157 is most often stacked with TB-500 for soft-tissue work. The community-named 'KLOW blend' (GHK-Cu + BPC-157 + TB-500 + KPV) gets pitched as a 'total repair package.' Marketing aside, the four-peptide combo is real and widely sold by grey-market vendors as a single vial.
Science journalist tracing the path from Predrag Sikiric's Croatian lab (1990s) to MAHA-aligned wellness use found a strong gap between rodent evidence and human claims. The community is increasingly aware of this gap — many self-experimenters now frame BPC-157 as 'promising in animals, watch your sources, take the gut/joint anecdotes seriously but don't bet your life on them.'
Most efficacy data is rodent. The FDA placed BPC-157 on a 503A bulks list under review in 2023; final disposition pending. No long-term human safety data.
Mechanistically distinct — hits a different pathway.
Stack doesn't rank peptides — we surface the diversity of opinion. Each card paraphrases a public-record stance from a named source. Where they conflict is where you should slow down and read both.
B-tier in his ranking — situational, only run for an actual injury, local injection near the affected site. Doesn't believe it's a daily-use compound; skeptical of dramatic recovery claims he hasn't personally experienced.
Established clinical use for soft-tissue injury and gut barrier repair. Dosing protocols documented in his published peptide reference. Clinical experience predates the FDA Category 2 ban — most US compounding pharmacies stopped supplying in 2023.
Strong rodent and rabbit data for tendon/ligament repair, gut healing, and angiogenesis. Human RCT data is sparse — no Phase 3 trials registered. The mechanistic argument outpaces the human evidence base.
Source →Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Pre-filled with this compound's published dose range: 250-500 µg · daily, subcutaneous
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
How much a first cycle actually costs across the channels people use. Pick the protocol length you're considering — Stack multiplies the monthly band by cycle weeks. Same caveats apply: ranges are facts, quality varies, this is not legal advice.
Numbers reflect publicly-advertised price ranges, not vendor quotes. Insurance, prescription costs, and shipping aren't included. Channels marked unavailable are filtered out.
See pharmacies for this compound →Approximate monthly cost across the channels users actually consider — brand FDA-approved retail, US 503A compounding, Mexican pharmacies, MX farmacias magistrales, and the research-grey market. Stack lists ranges, not vendor names. Quality varies wildly across channels — see each band's note.
Dosing assumption: 250-500 mcg daily subcutaneous, 4-6 week protocols
Not currently legal in US — Cat-2 since 2023, awaiting PCAC review July 2026. Some 503A pharmacies suspended supply pending decision.
As of 2026-04MX farmacias magistrales prepare BPC-157 without the FDA Cat-2 ban that constrains US compounding. Cross-border legitimate access exists.
As of 2026-04Research-grey range. Most US users since 2023 ban access via this channel — counterfeit and underdosed product common.
As of 2026-04Public-source attribution across the production + distribution chain. Stack does not endorse vendors — this is who is in the chain, not which one is best.
BPC-157 · TB-500 · Sermorelin · CJC-1295/Ipamorelin · Semaglutide · Tirzepatide
Houston-based 503A compounding pharmacy, one of the largest in the US peptide compounding market.
BPC-157 · TB-500 · Sermorelin · CJC-1295/Ipamorelin
BPC-157 · Sermorelin · CJC-1295/Ipamorelin
Sermorelin · Ipamorelin · BPC-157
One of the most consistently recommended vendors on r/Peptides since the Peptide Sciences shutdown (March 2026). Third-party COA published per batch. HPLC purity ≥99%.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Long-established US vendor (7+ years). Broad catalog including GHRPs, GHRHs, and cognitive peptides. Third-party HPLC and mass-spec COA per batch. Active Finnrick Analytics coverage.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Newer vendor with fast turnaround and competitive pricing. Third-party COA on all products. Building Finnrick coverage. Frequently recommended post-Peptide Sciences shutdown.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Established vendor with multi-year community track record. Offers peptide blends (Wolverine Stack, etc.) alongside singles. Third-party COA available on request.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Known for above-average catalog depth, including harder-to-find compounds (SS-31, humanin, Foxo4-DRI). Third-party HPLC published. Active Finnrick coverage.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Clean storefront, competitive pricing, strong community mentions. Third-party COA on most products. Ships to US with fast turnaround.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Tampa-based telehealth clinic specializing in hormone and peptide therapy. Prescribing provider + compounding pharmacy fulfillment. BPC-157, CJC/Ipa, Ipamorelin, PT-141, Sermorelin. Prescription required.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
FDA Cat. 2 removed Apr 2026 — PCAC review Jul 23-24, 2026
FDA's Pharmacy Compounding Advisory Committee scheduled to review the first cohort of peptides removed from Category 2 in April 2026. The 7 peptides on this docket are the highest-profile community names — BPC-157, TB-500, MOTS-c, Epitalon, DSIP, Semax, KPV.
FDA published a Federal Register notice on April 15 2026 removing 12 peptides from the Category 2 ('significant safety concerns') compounding list, paving the way for PCAC review for inclusion on the 503A bulks list. Peptides removed: BPC-157, TB-500, Epitalon, GHK-Cu (injectable), MOTS-c, DSIP, Dihexa Acetate, MK-677, Melanotan II, KPV, Semax, LL-37.
FDA's Pharmacy Compounding Advisory Committee categorized a wide list of peptides as Category 2 ('significant safety concerns'), effectively banning their compounding at 503A and 503B pharmacies. Affected: BPC-157, TB-500, Epitalon, GHK-Cu, MOTS-c, DSIP, Dihexa, MK-677, Melanotan II, KPV, Semax, Selank, LL-37 and others.
COFEPRIS regulates Mexican farmacias magistrales (compounding pharmacies) under different rules than the US 503A bulks-list framework. Several Mexican compounding pharmacies prepare BPC-157, TB-500, CJC-1295/Ipamorelin, Tesamorelin, and GHK-Cu without the FDA Category 2 ban that has constrained US compounding since 2023.